This document is an internal email from the U.S. Attorney's Office for the Southern District of New York, detailing the press conference announcement for the arrest of Ghislaine Maxwell in July 2020.
The email, sent on June 30, 2020, contains a draft advisory for a press conference announcing charges against Ghislaine Maxwell for her role in the sexual exploitation of minor girls alongside Jeffrey Epstein. It outlines the logistics, including the speaker, Acting U.S. Attorney Audrey Strauss, and the timing. The document also references internal discussions about venue logistics and COVID-19 protocols, providing a behind-the-scenes look at the high-profile announcement.
From: USANYS)" To: a>, ' [Contractor]" Cc: 'aJSANYS)" >, (USANYS) (USANYS)" Subject: RE: COVID Language for Press Release Date: Tue, 30 Jun 2020 15:04:17 +0000 Attachments: Ghislaine_Maxwell_Press_Conference_7.1.2020_Draft_Advisoty.docx Inline-Images: image001.png; image003jpg I'm here in the press office, if needed. Draft advisory below and attached in Word format: United States Attorney Southern District of New York There will be a press conference today at XX:00 a.m. to announce charges against Ghislaine Maxwell for her role in the sexual exploitation and abuse of multiple minor girls by Jeffrey Epstein. The press conference will be livestreamed on Facebook @USAOSDNY. Relevant documents are attached. WHO: Audrey Strauss, Acting United States Attorney for the Southern District of New York , Assistant Director-in-Charge of the New York Office of the Federal Bureau of Investigation WHAT: Press Conference WHEN: Wednesday, July, I, 2020 xx:00 p.m. WHERE: U.S. Attorney's Office, Southern District of New York CONTACT: NOTE: Please silence all cell phones, PDAs, and pagers before start of press conference. MANDATORY COVID-19 PROTOCOLS WILL BE IN PLACE. CLICK HERE FOR GUIDANCE. EFTA00015353
DO NOT REPLY TO THIS MESSAGE. IF YOU HAVE QUESTIONS, PLEASE CALL THE PRESS OFFICE AT From: (USANYS) Sent: Tuesday, June 30, 2020 10:45 AM To: Cc: Subject: RE: COVID Language for Press Release (USANYS) [Contractor] (USANYS) >; (USANYS) (USANYS) < Thanks very much, M . Looping in • and Please do keep exploring the option. If it's doable it might beat out our lobby—definitely seems like a stronger visual. On that note, if it was possible for one of you to take Audrey on a walk-through of 290 as we figure it out, she'd appreciate it. From: (USANYS) [Contractor] Sent: Tuesday, June 30, 2020 10:38 AM To: (USANYS) <->; (USANYS) < Subject: RE: COVID Language for Press Release Wait, I thought we were now targeting the lobby of I just got off the phone with from the FBI press office, inquiring about the logistics of that. I think they can get chairs for press, check with GSA on their Covid protocols (capacity, etc.), provide a "step-and-repeat" (a portable background with "FBI" and their seal) to reduce glare from the windows on the Duane Street side. The concerns are the acoustics (as you know, that space is cavernous, with all hard surfaces and a high ceiling) and their lack of a podium (so we'd have to lug ours over there). Is our lobby preferable? I can call back and call off the dogs. From: (USANYS) < > Sent: Tuesday, June 30, 2020 10:15 AM To: (USANYS) [Contractor] Cc: (USANYS) Subject: COVID Language for Press Release (USANYS) (USANYS) < The International Court of Trade has said no, so it looks like we're likely at Plan B (Plan Z?) option of using our whole lobby space in an effort to create some social distance. With apologies for adding to your full plate, Audrey asked if you could please come up with a paragraph to put at the top of tomorrow's press advisory, notifying the press of safety protocols—masks, social distancing, etc.—and asking them to please leave extra time to get into the building (which may mean we should also send out the advisory earlier than usual). I've attached our safety protocols and am cc'ing El (and M , though he's out), since I know you'll want to coordinate with them on how press screening will work. Happy of course to talk or help in any way. Thanks! EFTA00015354


